Cardiol Therapeutics (NASDAQ:CRDL) Announces Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Key Points

• Cardiol Therapeutics reported quarterly EPS of ($0.04), beating analyst expectations of ($0.09) by $0.05.
• Shares rose 1.3% to $1.52, while the company’s market capitalization stood at approximately $176.15 million.
• Analyst sentiment remains mixed, with two Buy ratings and one Sell rating producing a consensus “Hold” rating and an $8.50 price target.

Cardiol Therapeutics (NASDAQ:CRDL - Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.05, Zacks reports.

Cardiol Therapeutics Trading Up 1.3%

NASDAQ:CRDL traded up $0.02 during midday trading on Wednesday, hitting $1.52. 790,566 shares of the company traded hands, compared to its average volume of 597,604. The firm has a market capitalization of $176.15 million, a P/E ratio of -5.43 and a beta of 0.72. The firm's fifty day moving average is $1.14 and its 200-day moving average is $1.17. Cardiol Therapeutics has a 12-month low of $0.88 and a 12-month high of $1.71.

Analysts Set New Price Targets

Several equities analysts have commented on CRDL shares. Wall Street Zen lowered shares of Cardiol Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, May 16th. HC Wainwright restated a "buy" rating on shares of Cardiol Therapeutics in a report on Tuesday, July 14th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Cardiol Therapeutics in a research report on Wednesday, June 24th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Cardiol Therapeutics has a consensus rating of "Hold" and a consensus price target of $8.50.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Bank of America Corp DE raised its stake in shares of Cardiol Therapeutics by 136.2% in the second quarter. Bank of America Corp DE now owns 26,455 shares of the company's stock valued at $36,000 after acquiring an additional 15,255 shares during the period. Two Sigma Investments LP bought a new position in Cardiol Therapeutics during the 3rd quarter valued at about $249,000. Virtu Financial LLC bought a new position in Cardiol Therapeutics during the 3rd quarter valued at about $154,000. Citadel Advisors LLC grew its stake in shares of Cardiol Therapeutics by 1,132.6% during the third quarter. Citadel Advisors LLC now owns 463,462 shares of the company's stock valued at $496,000 after buying an additional 425,862 shares during the last quarter. Finally, Susquehanna International Group LLP increased its stake in Cardiol Therapeutics by 366.5% in the third quarter. Susquehanna International Group LLP now owns 93,398 shares of the company's stock worth $100,000 after purchasing an additional 73,375 shares during the period. Institutional investors own 12.49% of the company's stock.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc NASDAQ: CRDL is a clinical-stage pharmaceutical company dedicated to developing immunomodulatory treatments for patients with cardiovascular disease. The company's lead asset, CardiolRx, is a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation designed to target the inflammation and oxidative stress underlying conditions such as acute myocardial injury and heart failure. Cardiol holds exclusive global rights to CardiolRx through a licensing partnership and is advancing additional preclinical programs focused on small-molecule immunotherapies for heart disease.

CardiolRx is formulated for oral administration and has been evaluated in a randomized, placebo-controlled Phase 2 myocardial protection study assessing safety and key biomarkers following acute coronary syndromes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source